The role of glycoprotein IIb/IIIa-receptor antagonists in diabetics.
GP IIb/IIIa-receptor-inhibitors have been shown to be effective antithrombotic agents as adjunct therapy in patients with unstable angina/non ST-elevation myocardial infarction, but also in stable and unstable patients who undergo percutaneous coronary interventions. It has been emphasized by several investigators that diabetics belong to a high-risk patient group in which a special benefit from the use of GP IIb/IIIa-inhibitors might be expected. Among these agents, most consistent data in diabetic patients are presently available for abciximab. In general, GP IIb/IIIa-antagonists have been shown to be effective in diabetics by retrospective subgroup analyzes and meta-analyzes. Prospective trials with well prespecified patient groups are missing and would be mandatory to bring more light into a still developing field.
Huber
Kurt
K
3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria. kurt.huber@wienkav.at
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab